GlassScriptPhysician profile
Selvakumar Chockalingam
NPI 1306889357
$8,828.31
in general payments reported to CMS, 2019-2025
30 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $970 · 2021: $1,650 · 2022: $1,522 · 2023: $1,627 · 2024: $1,099 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,477 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,477.37 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,162.57 | 2019-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $1,067.35 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $925.28 | 2019-2025 | |
| Pfizer INC. | $910.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $842.54 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $771.94 | 2019-2022 | |
| Biotronik INC. | $651.52 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Amgen INC. | $415.91 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $277.92 | 2020-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.49 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $231.18 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.89 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $139.52 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $137.50 | 2022-2025 | Verquvo |
| Welch Allyn | $125.68 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $113.53 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $109.13 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $88.76 | 2019-2021 | |
| Amarin Pharma, INC. | $86.01 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $52.61 | 2019 | |
| Kestra Medical Technology Services, INC. | $49.44 | 2023 | Assure Wcd |
| Boston Scientific Corporation | $29.65 | 2023 | Watchman Access System |
| Medtronic Vascular, INC. | $24.83 | 2019 | |
| Medtronic, INC. | $24.11 | 2022 | |
| Atricure, INC. | $23.79 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.93 | 2022 | |
| Cvrx, INC. | $20.25 | 2024 | Barostim Neo System |
| Abbott Laboratories | $13.86 | 2020 | |
| Chiesi USA, INC. | $13.80 | 2023 | Kengreal, Cleviprex |
| Gilead Sciences, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selvakumar Chockalingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.